WHO suspends clinical trails of hydroxychloroquine over safety concern
WHO suspends clinical trails of hydroxychloroquine over safety concern The Lancet study found that both drugs can produce potentially serious side effects, particularly heart arrhythmia. The World Health Organization (WHO) said on Monday it had temporarily suspended clinical trials of hydroxychloriquine as a potential treatment for carried Covid-19 being carried out across a range of countries as a precautionary measure. The decision came after publication last week of a study in The Lancet which indicated that using the drug on COVID-19 patients could increase their chances of dying, WHO chief Tedros Adhanom Ghebreyesus told a virtual press conference. Mr. Tedros said that the executive group of the so-called Solidarity Trial, in which hundreds of hospitals across several countries have enrolled patients to test several possible treatments for the novel coronavirus, had as a precaution suspended trials using that drug. “The Execut...
